Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorma Isola

Showing results (51-60 of 145) with videos related to

Pageof 15
Sort By:
Breast Cancer Research and Treatment|July 20, 2007
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancerLooket Dihge, Pär-Ola Bendahl, Dorthe Grabau, et al.
Gynecologic Oncology|January 31, 2004
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinomaHeini Lassus, Arto Leminen, Aki Vayrynen, et al.
Cancer Letters|January 7, 2020
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancerMark Barok, Vadim Le Joncour, Ana Martins, et al.
Journal of Molecular Medicine (Berlin, Germany)|April 12, 2006
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinomaHeini Lassus, Harri Sihto, Arto Leminen, et al.
Cancer Letters|March 3, 2010
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cellsKatri Köninki, Mark Barok, Minna Tanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patientsTeemu T Junttila, Matti Laato, Tero Vahlberg, et al.
Cancer Genetics and Cytogenetics|June 18, 2003
Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell linesSatu-Leena Sallinen, Pauli Sallinen, Minna Ahlstedt-Soini, et al.
Cancer Research|February 7, 2002
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancerAri Ristimäki, Anna Sivula, Johan Lundin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridizationJorma Isola, Minna Tanner, Amanda Forsyth, et al.
Cancer Research|August 28, 2003
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomasFan Zhang, Mikael Lundin, Ari Ristimäki, et al.
Pageof 15

Showing results (51-60 of 145) with videos related to

Sort By:
Pageof 15
Breast Cancer Research and Treatment|July 20, 2007
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancerLooket Dihge, Pär-Ola Bendahl, Dorthe Grabau, et al.
Gynecologic Oncology|January 31, 2004
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinomaHeini Lassus, Arto Leminen, Aki Vayrynen, et al.
Cancer Letters|January 7, 2020
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancerMark Barok, Vadim Le Joncour, Ana Martins, et al.
Journal of Molecular Medicine (Berlin, Germany)|April 12, 2006
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinomaHeini Lassus, Harri Sihto, Arto Leminen, et al.
Cancer Letters|March 3, 2010
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cellsKatri Köninki, Mark Barok, Minna Tanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patientsTeemu T Junttila, Matti Laato, Tero Vahlberg, et al.
Cancer Genetics and Cytogenetics|June 18, 2003
Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell linesSatu-Leena Sallinen, Pauli Sallinen, Minna Ahlstedt-Soini, et al.
Cancer Research|February 7, 2002
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancerAri Ristimäki, Anna Sivula, Johan Lundin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridizationJorma Isola, Minna Tanner, Amanda Forsyth, et al.
Cancer Research|August 28, 2003
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomasFan Zhang, Mikael Lundin, Ari Ristimäki, et al.
Pageof 15